Novel asset evaluation in antibody mediated rejection
Provide an initial assessment of the current treatment landscape, challenges and unmet needs. Provide robust metrics identify the potential uptake of the novel asset that can be modelled depending on the outcome of the ongoing trial (and in case of new competitors)
Stage 1: Interviews (qualitative) with KOLs and high-level treaters to validate and reduce the product attribute list
Stage 2: Wide-scale quantitative survey of KOLs and high-level treaters including adaptive choice-based conjoint
We showed potential for success in the category based on the relative strength of product attributes and trial outcomes. Our simulator demonstrated a less than the originally targeted efficacy would not unduly affect success at launch. Our use of ‘what if scenarios’ helped our client to adapt their commercial evaluation to several eventualities in terms of the future landscape.